Surrozen, Inc./DE Increase (Decrease) in Accrued Liabilities
Surrozen, Inc./DE (SRZN) reported Increase (Decrease) in Accrued Liabilities of -$1.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$799.00K, a 491.67% decline year-over-year.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.16M.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.94M, a 239.93% increase year-over-year.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $555.00K, a 17.66% decline year-over-year.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for fiscal 2025 was $2.50M, a 137.03% increase from fiscal 2024.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for fiscal 2024 was $1.06M.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for fiscal 2023 was -$2.55M.
- Surrozen, Inc./DE increase (decrease) in accrued liabilities for fiscal 2022 was -$1.78M, a 147.03% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 4 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$799.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.96M 10-Q · filed 2026-08-06 | $975.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.53M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$1.16M 10-Q · filed 2026-05-06 | $1.77M derived: sum of 2 quarters · filed 2026-05-06 | $2.33M derived: sum of 3 quarters · filed 2026-05-06 | $2.53M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.49M derived: sum of 2 quarters · filed 2026-03-23 | $3.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $555.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $759.00K derived: sum of 2 quarters · filed 2026-08-06 | -$434.00K 10-Q · filed 2025-11-07 | $430.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$989.00K 10-Q · filed 2026-08-06 | -$125.00K derived: sum of 3 quarters · filed 2026-08-06 | $549.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$1.19M 10-Q · filed 2026-05-06 | -$329.00K derived: sum of 2 quarters · filed 2026-05-06 | $345.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.00M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $864.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.54M derived: sum of 2 quarters · filed 2026-03-23 | $2.20M derived: sum of 3 quarters · filed 2026-03-23 | $1.06M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $674.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.33M derived: sum of 2 quarters · filed 2025-11-07 | $192.00K 10-Q · filed 2025-11-07 | $370.00K derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $658.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$482.00K 10-Q · filed 2025-08-08 | -$304.00K derived: sum of 3 quarters · filed 2025-08-08 | -$230.00K derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | -$1.14M 10-Q · filed 2025-05-09 | -$962.00K derived: sum of 2 quarters · filed 2025-05-09 | -$888.00K derived: sum of 3 quarters · filed 2025-05-09 | -$2.30M derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | $178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $252.00K derived: sum of 2 quarters · filed 2025-03-31 | -$1.16M derived: sum of 3 quarters · filed 2025-03-31 | -$2.55M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.34M derived: sum of 2 quarters · filed 2024-11-06 | -$2.73M 10-Q · filed 2024-11-06 | -$2.08M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$2.80M 10-Q · filed 2024-08-12 | -$2.15M derived: sum of 3 quarters · filed 2024-08-12 | -$1.99M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$1.39M 10-Q · filed 2024-05-08 | -$736.00K derived: sum of 2 quarters · filed 2024-05-08 | -$579.00K derived: sum of 3 quarters · filed 2024-05-08 | $613.00K derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $808.00K derived: sum of 2 quarters · filed 2024-04-10 | $2.00M derived: sum of 3 quarters · filed 2024-04-10 | -$1.78M 10-K · filed 2024-04-10 | |||
| 2022-09-30 | $157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.35M derived: sum of 2 quarters · filed 2023-11-08 | -$2.43M 10-Q · filed 2023-11-08 | -$1.76M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.59M 10-Q · filed 2023-08-09 | -$1.92M derived: sum of 3 quarters · filed 2023-08-09 | -$1.05M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | -$3.78M 10-Q · filed 2023-05-10 | -$3.11M derived: sum of 2 quarters · filed 2023-05-10 | -$2.24M derived: sum of 3 quarters · filed 2023-05-10 | -$1.79M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.54M derived: sum of 2 quarters · filed 2023-03-31 | $1.99M derived: sum of 3 quarters · filed 2023-03-31 | $3.79M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $875.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.32M derived: sum of 2 quarters · filed 2022-11-14 | $3.12M 10-Q · filed 2022-11-14 | $3.92M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $445.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.25M 10-Q · filed 2022-08-11 | $1.25M 10-Q · filed 2021-08-09 | $3.04M derived: sum of 3 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $1.80M 10-Q · filed 2022-05-11 | $696.44K 10-Q · filed 2021-05-24 | $2.60M derived: sum of 2 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $798.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $290.15K 10-K/A · filed 2021-05-14 | $1.90M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $1.10M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |